ReviewMissouri medicine
A Review of Direct-to-Consumer Home Antibiotic Kits: A Threat to Antimicrobial Stewardship and Patient Safety.
Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Driven by the global wellness industry, pandemic anxiety, and increasing demand for telehealth, a direct-to-consumer (DTC) market for prescription antibiotic emergency kits has emerged. This review examines the clinical, ethical, and public health risks of stockpiling broad-spectrum antimicrobials for self-administration without guidance from a clinician. This model is a health risk to the individual consumers (adverse effects, drug interactions) and to the entire population (propagating antimicrobial resistance). While these kits are marketed as tools of safety and peace of mind, they represent an unmonitored public health threat. This article concludes with a call to action for regulatory bodies and medical societies to investigate misleading marketing and enforce stricter rules on prescribing antibiotics for future hypothetical illnesses, except in high-risk travel medicine contexts.
Indexed as
Identifiers
42756965PMC13585011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.